CEPHAELINE SENSITIZES CISPLATIN AND REDUCES ORAL SQUAMOUS CELL CARCINOMA CANCER STEM CELLS

Abstract

Objective To evaluate the anticancer properties of Cephaeline on Oral Squamous Cell Carcinoma (OSCC) cell lines, including cancer stem cell (CSC) maintenance. Study Design SCC4, SCC9, and SCC25 OSCC cell lines were used. Cell viability was assessed by MTT. The presence of CSC was evaluated by tumorsphere formation. The histone acetylation (H3K9ac) status was determined by immunofluorescence staining. Results A single administration of Cephaeline disrupted CSC by reducing the tumorsphere. Additionally, cephaeline impacted the histone acetylation status, and a concomitant therapy with CDDP reduces the concentration of CDDP required to achieve IC50 in two cell lines (SCC4 and SCC9). Conclusion Our findings suggest that Cephaeline has anti-cancer properties in OSCC, disrupting the ability of cancer cells to generate tumorspheres. Moreover, this may represent an adjunct therapy to conventional treatments for OSCC. In vivo studies are needed to validate these findings. Funding FAPESP 2016/05710-4 To evaluate the anticancer properties of Cephaeline on Oral Squamous Cell Carcinoma (OSCC) cell lines, including cancer stem cell (CSC) maintenance. SCC4, SCC9, and SCC25 OSCC cell lines were used. Cell viability was assessed by MTT. The presence of CSC was evaluated by tumorsphere formation. The histone acetylation (H3K9ac) status was determined by immunofluorescence staining. A single administration of Cephaeline disrupted CSC by reducing the tumorsphere. Additionally, cephaeline impacted the histone acetylation status, and a concomitant therapy with CDDP reduces the concentration of CDDP required to achieve IC50 in two cell lines (SCC4 and SCC9). Our findings suggest that Cephaeline has anti-cancer properties in OSCC, disrupting the ability of cancer cells to generate tumorspheres. Moreover, this may represent an adjunct therapy to conventional treatments for OSCC. In vivo studies are needed to validate these findings.